Global Reach Stago is a world leader in In-Vitro Diagnostics with distribution in over 110 countries and a recent revenue achievement of approximately $880 million, presenting a large, multinational target market for additional instrumentation, reagents, and service contracts.

Private Ownership Privately owned and independent, Stago may be more open to strategic partnerships, collaborations, or private equity-backed expansion opportunities, especially given recent acquisition activity by Archimed Diagnostics and La Caisse.

Coagulation Focus Specialization in thrombosis and haemostasis and a growing portfolio of haemostasis analyzers (like sthemO 301) and near-patient testing tools create cross-sell options for laboratories expanding coagulation testing capacity and moving toward point-of-care solutions.

Innovation Pipeline Recent launches and partnerships (sthemO 301, qLabs FIB, MyOptiLab service, i-SEP distribution) indicate a strong R&D and services strategy, suggesting sales opportunities in instrument upgrades, disposables, reagents, and value-added services.

Healthcare Footprint From hospital deployments (Royal Sussex County Hospital) to NHS-affiliated settings and 110+ countries, there is potential to target large healthcare systems for multi-site contracts, maintenance agreements, training programs, and regional service expansions.